Compare Axogen Inc (AXGN) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs Charles Schwab Corporation Common Stock — how do they compare? Axogen Inc trades at $38.86 (market cap $2.06B), while Charles Schwab Corporation Common Stock trades at $103.2 (market cap $175.83B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 85.4× Axogen Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.27% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | SCHW | |
|---|---|---|
Market Cap | $2.06B | $175.83B |
Sector | Technology | Financials |
52-Week High | $46.19 | $107.21 |
52-Week Low | $11.28 | $85.35 |
Enterprise Value | $1.98B | — |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
Charles Schwab (SCHW) trades at $102.38, down 0.72% on the day, with a bullish technical outlook and strong fundamentals. Recent earnings beats, including Q1 2026 EPS of $1.43 versus $1.40 expected, highlight robust profitability. The stock is supported by a 21.79% ROE and a net income margin of 37.99%, with revenue growth to $23.92 billion in 2025. Positive sentiment is fueled by a Zacks Strong Buy upgrade and a consensus price target of $122.71, suggesting 20% upside.
Outlook remains favorable given earnings momentum and retail trading growth, but risks include interest rate sensitivity and competitive pressures. Analyst consensus is 58% buy, with institutional confidence bolstered by a recent dividend payment. The stock's valuation at a P/E of 20.35 appears reasonable relative to growth, though high RSI levels indicate potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
